HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages ...

Roflumilast cream 0.05% provides durable efficacy and is well-tolerated for up to 56 weeks in children aged 2-5 years with mild-to-moderate atopic dermatitis, a study finds.

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved ...

Credit: Getty Images. No new safety signals were observed in this patient population. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ruxolitinib ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...